 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546» |
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (clinicaltrials.gov) - Jul 15, 2015
P3, N=500, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting
- Trial completion, Enrollment change: Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART (clinicaltrials.gov) - Jul 15, 2015
P0, N=105, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=140 --> 105
- |||| efavirenz / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Trial primary completion date, Adherence: PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (clinicaltrials.gov) - Jun 25, 2015
P4, N=400, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed | N=140 --> 105 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Sep 2014
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion: Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa (clinicaltrials.gov) - Jun 24, 2015
P4, N=280, Completed, Sponsor: University of Zambia
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Sep 2014 Active, not recruiting --> Completed
- |||||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial primary completion date: Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (clinicaltrials.gov) - Jun 17, 2015
P3, N=612, Recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Apr 2017
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Jun 11, 2015
P4, N=12, Recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Apr 2017 Trial primary completion date: Oct 2015 --> Feb 2017
- || lopinavir/ritonavir / Generic mfg.
Trial initiation date, Trial primary completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=3200, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Oct 2015 --> Feb 2017 Initiation date: Jan 2005 --> Aug 2006 | Trial primary completion date: Jan 2018 --> Jan 2016
- |||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (clinicaltrials.gov) - Jun 11, 2015
P3, N=500, Not yet recruiting, Sponsor: Gilead Sciences
- || Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial primary completion date: Effects of Intensive cART During Acute/Early HIV Infection (clinicaltrials.gov) - Jun 1, 2015
P2/3, N=32, Completed, Sponsor: University of Toronto
Initiation date: Jan 2005 --> Aug 2006 | Trial primary completion date: Jan 2018 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Sep 2014
- | lopinavir/ritonavir / Generic mfg.
Trial completion: ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment (clinicaltrials.gov) - May 29, 2015
P1, N=40, Completed, Sponsor: Institut de Recherche pour le Developpement
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Sep 2014 Active, not recruiting --> Completed
- ||||||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial completion: Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (clinicaltrials.gov) - May 26, 2015
P3, N=724, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || lopinavir/ritonavir / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - May 22, 2015
P=N/A, N=550, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=450 --> 550 | Trial primary completion date: Feb 2018 --> Jan 2016
- | efavirenz / Generic mfg., rifampicin / Generic mfg.
Trial completion, Trial primary completion date: A06-295: An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin (clinicaltrials.gov) - May 19, 2015
P4, N=30, Completed, Sponsor: Oswaldo Cruz Foundation
N=450 --> 550 | Trial primary completion date: Feb 2018 --> Jan 2016 Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Dec 2012
- lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: AP6142: Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) (clinicaltrials.gov) - May 7, 2015
P1, N=18, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Dec 2012 Active, not recruiting --> Completed | N=24 --> 18
- New trial: LEOPARD: Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (clinicaltrials.gov) - May 1, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Columbia University
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 28, 2015
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=24 --> 18 Trial primary completion date: May 2016 --> Jun 2018
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open: EIT: Early Infant HIV Treatment in Botswana (clinicaltrials.gov) - Apr 28, 2015
P2/3, N=70, Recruiting, Sponsor: Harvard School of Public Health
Trial primary completion date: May 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- | efavirenz / Generic mfg., abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: NEVEREST-III: Treatment Options for Protease Inhibitor-exposed Children (clinicaltrials.gov) - Apr 23, 2015
P3, N=300, Completed, Sponsor: Columbia University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=400 --> 300
- VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics, VRC01 / Acuitas Therap
Trial initiation date, Trial primary completion date: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (clinicaltrials.gov) - Apr 19, 2015
P1/2, N=472, Recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Completed | N=400 --> 300 Initiation date: Jun 2014 --> Jan 2015 | Trial primary completion date: May 2022 --> Dec 2023
- lopinavir/ritonavir / Generic mfg.
Trial initiation date, Trial primary completion date: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (clinicaltrials.gov) - Apr 19, 2015
P4, N=50, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Initiation date: Jun 2014 --> Jan 2015 | Trial primary completion date: May 2022 --> Dec 2023 Initiation date: Sep 2014 --> Jul 2015 | Trial primary completion date: Jun 2015 --> Sep 2016
- | Mycobutin (rifabutin) / Pfizer, Lupin
New P2 trial: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly (clinicaltrials.gov) - Apr 14, 2015
P2, N=40, Not yet recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (clinicaltrials.gov) - Apr 1, 2015
P4, N=240, Completed, Sponsor: Hospital Clinic of Barcelona
Initiation date: Sep 2014 --> Jul 2015 | Trial primary completion date: Jun 2015 --> Sep 2016 Recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (clinicaltrials.gov) - Apr 1, 2015
P4, N=240, Completed, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Completed Recruiting --> Completed
- Clinical: PK TDF in Thai HIV-infected Children (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=32, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
- efavirenz / Generic mfg.
Enrollment closed: LAAM-HAART PET Imaging (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=8, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Recruiting --> Active, not recruiting
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial primary completion date: Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy (clinicaltrials.gov) - Mar 31, 2015
P2, N=40, Active, not recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2012 --> Dec 2015
- | lopinavir/ritonavir / Generic mfg.
Trial completion, Trial primary completion date: Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children (clinicaltrials.gov) - Mar 26, 2015
P2, N=24, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2012 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2011
- lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: TDM of Generic Lopinavir/Ritonavir 200/50 mg (clinicaltrials.gov) - Mar 26, 2015
P2, N=70, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2011 Active, not recruiting --> Completed | N=100 --> 70
- didanosine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial primary completion date: IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (clinicaltrials.gov) - Mar 25, 2015
P4, N=1653, Active, not recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Completed | N=100 --> 70 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2016
- ||||||| lopinavir/ritonavir / Generic mfg.
Trial completion: Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) (clinicaltrials.gov) - Mar 25, 2015
P3, N=199, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2016 Active, not recruiting --> Completed
- || Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Mar 11, 2015
P2, N=100, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Aug 2016
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2015 --> Aug 2016 N=84 --> 0
- Isentress (raltegravir) / Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date: Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection (clinicaltrials.gov) - Mar 7, 2015
P2/3, N=40, Recruiting, Sponsor: Funda
N=84 --> 0 Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Mar 2015 | Trial primary completion date: May 2015 --> Feb 2016
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE) (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Mar 2015 | Trial primary completion date: May 2015 --> Feb 2016 Trial primary completion date: Sep 2016 --> Apr 2017
- || Aikening (albuvirtide) / Frontier Biotech
New P3 trial: TALENT: Test Albuvirtide in Experienced Patients (clinicaltrials.gov) - Feb 24, 2015
P3, N=420, Recruiting, Sponsor: Frontier Biotechnologies Co., Ltd
- || nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P2/3 trial: EIT: Early Infant HIV Treatment in Botswana (clinicaltrials.gov) - Feb 24, 2015
P2/3, N=70, Not yet recruiting, Sponsor: Harvard School of Public Health
- || lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial initiation date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=3000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Sep 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Initiation date: Aug 2006 --> Jan 2005
- || lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial initiation date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=450, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Initiation date: Aug 2006 --> Jan 2005 Recruiting --> Active, not recruiting | Initiation date: Dec 2008 --> Jun 2006
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: PROMISE: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=3485, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Initiation date: Dec 2008 --> Jun 2006 Trial primary completion date: Sep 2016 --> Apr 2017
- Trial primary completion date: Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (clinicaltrials.gov) - Feb 11, 2015
P1/2, N=52, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Sep 2016 --> Apr 2017 Trial primary completion date: Nov 2014 --> Oct 2015
- Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Feb 11, 2015
P2, N=471, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Nov 2014 --> Oct 2015 Trial primary completion date: Oct 2015 --> Nov 2016
- | rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P4 trial: Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB (clinicaltrials.gov) - Jan 28, 2015
P4, N=90, Recruiting, Sponsor: Drugs for Neglected Diseases
- | Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Trial primary completion date, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Jan 15, 2015
P2, N=40, Active, not recruiting, Sponsor: McGill University Health Center
Trial primary completion date: Oct 2015 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2015
- | abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, IO biomarker: Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV (clinicaltrials.gov) - Dec 22, 2014
P3, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2015 Active, not recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=3, Terminated, Sponsor: University of Maryland
Active, not recruiting --> Completed N=100 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2009 --> May 2009; Inability to enroll subjects.
- efavirenz / Generic mfg.
Trial primary completion date: LAAM-HAART PET Imaging (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=8, Recruiting, Sponsor: Washington University School of Medicine
N=100 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2009 --> May 2009; Inability to enroll subjects. Trial primary completion date: Dec 2014 --> Aug 2015
- nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Dec 5, 2014
P4, N=240, Recruiting, Sponsor: University of Cape Town
Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Feb 2014 --> Feb 2015
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Dec 5, 2014
P4, N=12, Recruiting, Sponsor: University of Miami
Trial primary completion date: Feb 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date: Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). (clinicaltrials.gov) - Nov 19, 2014
P4, N=22, Completed, Sponsor: Juan A. Arnaiz
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2010 --> Nov 2014
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: Surveillance of Kaletra in Korean Patients (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=591, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | Trial primary completion date: Aug 2010 --> Nov 2014 Active, not recruiting --> Completed